KalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $28.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently weighed in on KALV. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp reduced their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a report on Tuesday, November 11th. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Finally, JMP Securities boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

KalVista Pharmaceuticals Trading Up 11.9%

NASDAQ:KALV opened at $16.40 on Thursday. The company has a market capitalization of $829.02 million, a PE ratio of -4.15 and a beta of -0.14. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $17.28. The stock’s 50 day moving average price is $12.21 and its 200 day moving average price is $12.97. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. On average, research analysts anticipate that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 10,940 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $147,143.00. Following the transaction, the chief executive officer directly owned 416,189 shares of the company’s stock, valued at $5,597,742.05. This represents a 2.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the sale, the chief financial officer directly owned 10,529 shares in the company, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 31,329 shares of company stock worth $432,485. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its position in shares of KalVista Pharmaceuticals by 154.5% in the first quarter. Invesco Ltd. now owns 39,804 shares of the specialty pharmaceutical company’s stock valued at $459,000 after purchasing an additional 24,164 shares during the last quarter. Emerald Advisers LLC raised its position in shares of KalVista Pharmaceuticals by 15.6% during the 2nd quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock worth $11,735,000 after purchasing an additional 139,859 shares during the last quarter. Emerald Mutual Fund Advisers Trust lifted its stake in KalVista Pharmaceuticals by 26.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after buying an additional 160,759 shares in the last quarter. Woodline Partners LP grew its holdings in KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock valued at $18,666,000 after buying an additional 329,068 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in KalVista Pharmaceuticals by 2.8% during the first quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company’s stock worth $1,457,000 after buying an additional 3,405 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).